“These findings suggest that primary care may be exerting a protective effect on postoperative morbidity and mortality,” wrote Sanford E. Roberts, MD, of the University of Pennsylvania in Philadelphia, and co-authors in JAMA Surgery.

Of note, Black patients with PCP exposure had similar adjusted odds of in-hospital mortality relative to patients with no PCP exposure (OR 1.09, 95% CI 0.75−1.57), while white patients with PCP exposure had a 21% decreased risk of in-hospital mortality compared with the same group (OR 0.79, 95% CI 0.70−0.90).

However, at 30, 60, 90, and 180 days post-surgery, both Black and white patients who had visited a PCP had significantly lower adjusted odds of mortality compared with those who had not seen a PCP, with no significant differences in the interactions between race and PCP exposure for mortality.

Acute respiratory infection is caused by a wide range of pathogens, and an etiologic diagnosis is established in only about one third of cases. As a result, broad-spectrum antibiotics are often unnecessarily prescribed and continued. The BioFire FilmArray^® Pneumonia Panel (BioFire PN) is a commercial multiplex polymerase chain reaction (PCR) assay directed against 33 targets, including viruses, bacteria, and antibiotic resistance genes. In critically ill patients, BioFire PN results have shown a high level of agreement with culture results when tracheal aspirates (TA) or bronchoalveolar lavage fluid were sampled.

Now, in a comparative study, 298 samples (286 expectorated sputum and 12 from TA) deemed of good or moderate quality were obtained from hospitalized adult patients with acute respiratory or cardiopulmonary illness. BioFire PN detected a total of 1.23 bacterial pathogens per sample. Hemophilus influenzae was detected most often (33.0%), followed by Streptococcus pneumoniae and Staphylococcus aureus (20.5% for both), gram-negative bacilli (18.5%), and Moraxella catarrhalis (12.4%). Standard bacterial culture detected only 0.48 organisms per sample (compared with BioFire PN; P90%. Viral pathogens were detected in 51% of samples. Based on adjudication, the specificity of BioFire PN was only 45.0%. This was attributed to the greater number of potential pathogens identified compared with standard culture.

The North Carolina plant produces drugs that are injected or go through an IV.

The plant makes drugs for anesthesia, medicines that treat infections, and drugs needed for surgeries. The latter are used in surgeries or intensive care units for patients who are placed on ventilators, said Mike Ganio, who studies drug shortages at the American Society of Health-System Pharmacists.

The Pfizer site does not make or store the company’s COVID-19 vaccine or treatments Comirnaty and Paxlovid.

In a new study published in Nature Methods, researchers at the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany, describe improvements in the methods with which mutations can be introduced in human and other genomes—making these methods much more efficient and less error prone.

In the field of genome editing, scientists often need to change one letter—corresponding to one of the DNA bases Adenine, Guanine, Cytosine or Thymine—to another letter at one specific position in the genome. To do this, they use reagents that cut both strands of the DNA close to the position they want to change.

They then provide the cell with DNA molecules that contain the desired new letter in the hope that the cell’s repair systems will use these molecules to introduce the desired mutation when the DNA break is repaired. Since different repair systems in the cells compete with each other and only one of these systems is able to introduce the desired new mutation, applications of genome editing of single letters have so far been limited by low efficiency and unintended byproducts.